Tyra’s SURF302 Data Missed the Street’s 70% CR Bar
60 mg delivered 79% ORR and clean chronic-dosing safety, but 57% CR and a new 70 mg cohort missed the Street’s bar.
/ 3 items
#TYRA↓
Tyra Biosciences Faces Investor Pressure After Pushing Back Key Trial Timelines
TYRA shares fell after Q2 results showed delayed BEACH301 and SURF302 data, a wider $45.6M loss, and potential dilution from a new $250M ATM.
Tyra Biosciences Receives Buy Rating – Key 2026 Data Ahead
Tyra Biosciences’ dabogratinib shows promise: works well for bladder cancer & dwarfism with fewer side effects. Big 2026 trials ahead.